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Treatment for acute myeloid leukemia (AML) often includes several cycles of 
induction and/or consolidation chemotherapy and possible hematopoietic stem 
cell transplant (HSCT), all of which have the potential to impact the nutrition 
status of patients. We hypothesize that nutrition risk and the need for targeted 
nutrition interventions will change throughout treatment. 
In January 2017, Mayo Clinic began a descriptive pilot study with a goal accrual 
of 24 subjects in the first year. The aim of the study is to describe the nutrition 
evolution of patients undergoing treatment for AML and to compare nutrition 
screening and assessment tools in this patient population. 
 
Background 
Demographics of currently enrolled subjects (N=11) 
73% male (N=8), 27% female (N=3) 
Age at enrollment: 21 to 73 years old (mean 60, median 64) 
BMI at enrollment:  
• 9% (N=1) normal/healthy weight (BMI 18.5-24.9 kg/m2)  
• 55% (N=6) overweight (BMI 25-29.9 kg/m2) 
• 36% (N=4) obese (BMI ≥30 kg/m2) including (N=1) with a BMI >40 kg/m2 
Description of weight changes over time (N=10) 
• 91% (N=10) of subjects had at least one follow-up assessment 
• Weight loss ranged from 4.9% to 9.9% of pre-enrollment weight 
• Mean weight loss was 7.4% (median wight loss of 7.2%)  
• Greatest weight loss occurred between post-enrollment week three and 
week seven 
• Subjects for whom weights are available beyond week seven (N=3) have 
shown weight stabilization or weight regain after this time 
• 50% of subjects (N=5) had documented weight gain between enrollment and 
week 3, despite no edema noted on physical exam and worsening PG-SGA© 
scores  
• median PG-SGA© score increase in these subjects was +6 points  
PG-SGA / MST / current screening comparison 
The small number of study subjects limits comparability of scores at this point but 
observations from our initial results of the data (N=36) include: 
At enrollment 
• The current hospital admission nutrition screening tool did not identify any 
subjects (N=0) for RDN consult.    
• 36% (N=4) of subjects had an MST score of ≥2 indicating need for RDN consult 
• 91% (N=10) had a PG-SGA© score of ≥4 indicating RDN intervention required 
• 45% (N=5) of subjects had a PG-SGA© score of ≥9, indicating critical need for 
improved symptom management and/or nutrient intervention options (median 
PG-SGA score was 9, range 1-16) 
At first follow-up (week 3) 
• 82% (N=9) of subjects had a PG-SGA© score of ≥9 
• Median PG-SGA© score was 13.5 (range 7-22) 
• 64% (N=7) had a MST score of ≥2 
• Of the five hospital-based outpatient assessment scores: 
• 60% (N=3) had PG-SGA© scores of ≥9 
• 40% (N=2) had a MST score of ≥2 
Results 
Adult patients admitted to Mayo Clinic (Rochester, MN) hematology service 
are identified through hospital census. Subjects must be consented and 
respond in person (inpatient, hospital based outpatient, or ambulatory setting) 
to the researcher. Researchers include Registered Dietitian Nutritionists 
(RDNs) and Dietetic Interns who have received training in conducting nutrition 
focused physical exams (NFPE). 
Inclusion Criteria 
• Adults ≥18 years 
• New AML diagnosis 
• Able to read and understand English 
• Willing to answer questions using an iPad tablet 
Subjects are asked a series of questions related to their nutrition intake and 
history to assess their overall nutrition status. This series of questions is 
repeated every two to four weeks as subjects are followed during active 
treatment and recovery. These questions represent two distinct sets of 
questions: 
The first set of questions is a series  
of nutrition screening questions that  
constitute our hospital admission  
nutrition screening tool (Fig.1) and  
the validated Malnutrition Screening  
Tool (Fig.2), these questions are  
asked orally by the researcher.  
The second set of nutrition-related  
questions is the Patient Generated  
Subjective Global Assessment  
(PG-SGA©) and these questions are delivered via iPad tablet utilizing the Pt-
Global (pt-global.org) digital platform of the PG-SGA© (Fig.3) 
Subjects indicate their answers via touch screen to complete the weight, food 
intake, symptoms, and activities and functions portions (also referred to as the 
PG-SGA(SF).  The researcher then completes the professional portion of the 
PG-SGA© to include disease, metabolic demand (chart review of fevers, use of 
corticosteroids) and a nutrition focused physical exam to determine changes in 
fat stores, muscle stores, and presence of edema.   
 
Methods 
Figure 1 
• When compared to the MST and PG-SGA, the current hospital nutrition 
admission screening tool is not adequately identifying patients at risk for needing 
immediate RDN consult and intervention.      
• The MST score is derived primarily from weight loss and appetite. While this 
makes for a simple tool, it does not account for changes in patient function or 
symptoms beyond appetite that may be impacting nutrient intake.  
– The MST also does not take into account metabolic demand of disease, fever, 
or corticosteroids which are common in this patient population. 
• The existing evidence base for use of the PG-SGA© in patients with cancer is  
robust.  While the MST may be able to initially identify patients at nutrition risk, 
only the scored PG-SGA© has been shown to correlate with risk for adverse 
patient outcomes, including readmission rates, hospital stay, survival and quality 
of life.  
– For our subjects, PG-SGA© scores in weeks one through seven were driven 
primarily by patient-identified symptoms, patient-identified changes in activities 
and function, and by the presence of fevers. PG-SGA© scores beyond week 
seven were driven primarily by professional screen, with fat and muscle loss 
noted on nutrition focused physical exam being the most prevalent factors.  
• As we continue to enroll and follow subjects, there will likely be additional 
nutrition scoring trends identified. We expect that nutrition scoring trends will help 
identify patients at highest nutrition risk as early as possible.  
– Because at Mayo Clinic patients receive AML follow up care in a variety of 
settings (hospitalized inpatient, hospital-based outpatient, and ambulatory) 
being able to identify the highest risk patients through a screening tool is likely 
to be most efficient and effective. Finding a tool that is also precise in 
identifying the specific contributors to nutrition risk will also be valuable in 
targeting nutrition interventions for this patient population.  
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Introduction 
At Mayo Clinic, adult patients with Acute Myeloid Leukemia (AML) are treated in hospitalized 
inpatient, hospital-based outpatient, and traditional ambulatory outpatient settings. Access to a 
registered dietitian (RDN) varies in these settings and we hypothesize that this contributes to late 
identification of patients with potential increased nutrition risk. Because research on the nutrition 
evolution of patients with AML throughout the full continuum of treatment (induction through 
transplant) does not exist, specific nutrition intervention guidelines have not been established.   
Objectives 
This descriptive pilot study will determine what nutrition risk patterns exist among patients being 
treated for AML, from diagnosis through transplant. The study will compare the Malnutrition 
Screening Tool (MST), Patient-Generated Subjective Global Assessment© (PG-SGA) and current 
hospital admission malnutrition screening tool for specificity and sensitivity in this population.   
Methods 
At two to four week intervals subjects answered eight questions about their nutrition status. Three 
questions constitute the MST, the fourth is part of our hospital’s nutrition screening. The final four 
questions are the patient-generated portion of the PG-SGA©, or “short form” PG-SGASF©. Subjects 
completed the PG-SGASF© questions using a touchscreen application (Pt-Global v. 2.6, pt-
global.org). Researchers conducted nutrition focused physical exam and chart review to complete 
the full PG-SGA©. Results will be compared for specificity and sensitivity in determining nutrition risk.  
Results 
We have preliminary results from five subjects as of 2/14/17 and will have results from at least ten 
patients by June of 2017.  
Conclusions 
Results of this pilot study may contribute to evidence-based nutrition care guidelines for this 
population.  
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